Switch Therapeutics
Marina Kovaliov is an accomplished scientist with extensive experience in chemistry and biochemistry, currently serving as the Director of Chemistry and Principal Scientist at Switch Therapeutics since January 2022. Prior to this role, Marina held positions as a Senior Scientist at Nautilus Biotechnology and Principal Scientist and Group Leader at BioHybrid Solutions LLC. A significant part of Marina's career includes work at Allegheny Health Network as a Senior Research Scientist and Research Fellow in the Neuroscience Disruptive Research Laboratory. Marina's academic background includes a postdoctoral fellowship at the University of Pittsburgh, where research focused on drug candidates for cancer treatment, and a Ph.D. in Bioorganic Medicinal Chemistry from Bar-Ilan University. Earlier roles include research assistant positions in undergraduate programs, showcasing a commitment to synthesizing various biochemical compounds.
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.